TY - JOUR T1 - EOLIA trial: the future of extracorporeal membrane oxygenation in acute respiratory distress syndrome therapy? JF - Breathe JO - Breathe SP - 244 LP - 246 DO - 10.1183/20734735.0363-2018 VL - 15 IS - 3 AU - Muhammad Sameed AU - Zhou Meng AU - Ellen T. Marciniak Y1 - 2019/09/01 UR - http://breathe.ersjournals.com/content/15/3/244.abstract N2 - This was a prospective, multi-centre randomised controlled trial that involved centres in 16 countries. The trial was designed as a group sequential analysis with data analysed after randomisation of every 60 participants; stopping rules were predefined using the two triangle method. The trial could be stopped due to safety (due to excessive mortality in the ECMO arm), efficacy or futility (if unlikely to reach a definitive result). The trial was designed to have a power of 80% and alpha level of 5% to detect an absolute risk reduction of 20%. It was hypothesised that the mortality would be 60% in the conventional arm and 40% in the ECMO arm. Mortality at 60 days was the primary outcome measured.In the EOLIA trial, early use of ECMO did not significantly improve mortality at 60 days in patients with severe ARDS, but when used as a rescue modality ECMO might help improve survival http://bit.ly/2XOjwSE ER -